Racura Oncology

Racura Oncology is an Australian clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through its lead asset, RC220, a proprietary formulation of bisantrene. The company's therapeutic approach focuses on silencing the MYC oncogene and inhibiting the FTO protein by targeting G-quadruplex DNA and RNA structures. Currently, Racura is advancing a Phase 3 clinical program for relapsed or refractory acute myeloid leukaemia (AML) and Phase 1/2 trials for EGFR-mutant non-small cell lung cancer and advanced solid tumours. A distinguishing feature of RC220 is its potential to provide cardioprotection, mitigating the heart damage typically associated with anthracycline chemotherapies while simultaneously enhancing anti-tumor activity. Headquartered in Sydney and listed on the ASX, the company maintains strategic collaborations with premier institutions like MD Anderson and City of Hope.